Immunological and Clinical Aspects of Immune Responses to SARS-CoV-2

authors:

avatar Alireza Andalib 1 , * , avatar Maedeh Radandish 1

Department of Immunology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran.
Journal of Inflammatory Diseases: Vol.24, issue 6; 592-613
article type: issue_documents_importer

how to cite: Andalib A, Radandish M. Immunological and Clinical Aspects of Immune Responses to SARS-CoV-2. J Inflamm Dis. 2021;24(6):e156257. 

Abstract

The Coronavirus Disease 2019 (COVID-19) caused by a coronavirus named SARS-CoV-2 from the family Coronaviridae, was first reported in December 2019 in China. The disease have mild or severe symptoms such as fever, chills, cough, shortness of breath, body aches, and gastrointestinal symptoms, followed by severe inflammation, cytokine storm, acute respiratory distress syndrome, and dysfunction of other organs. In this narrative review study, the search was conducted on related studies published during January- October 2020 in Google Scholar, PubMed, Embase, and Scopus databases using the keywords Covid-19, Immunology, and Immunopathogenesis. Among abundant and mostly repetitive information, the immunological aspects were selected. The SARS-CoV-2 can enter the cell by binding to the Angiotensin-Converting Enzyme 2 (ACE2) receptor and Trans-Membrane Protease Serine 2 (TMPRSS2) on the surface of lung epithelial cells. The main pathogenic mechanism of infection with SARS-CoV-2 is the stimulation of inflammatory response followed by damage to the alveoli of lung tissue. In uncontrolled immune responses, the infiltration of macrophages, monocytes, neutrophils, and inflammatory T cells into the alveoli increases which leads to tissue damage in the lungs and other organs by overproduction of inflammatory cytokines such as Interleukin 6 (IL-6), Tumor Necrosis Factor alpha (TNF-α), Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF), Interleukin 6 (IL-8), Interferon gamma (IFNγ), etc. The Natural Killer (NK) and T cell dysfunction, lymphopenia, and infection of immune cells such as monocytes with ADE mechanism are factors causing the body’s failure in resistance to SARS-CoV-2 virus. Diagnosis of COVID-19 is based on the clinical symptoms and the results of molecular tests (e.g. Polymerase Chain Reaction test), or computerized tomography scan followed by serological tests and measuring biochemical factors in the blood (e.g. lymphocyte count, C-reactive protein, dimerized plasmin fragment D, etc.). Due to the association of the severity of COVID-19 with the uncontrolled immune response of the host, targeting any of the immunopathological pathways to inhibit inflammatory responses can be considered as potential therapeutic goals. The use of immune system regulators such as chloroquine, corticosteroids, inflammatory cytokine blockers such as anti-IL-6, anti-IL-1, and cell therapy at the right time have an enhanced effect on the recovery of the disease or inhibit the disease progression.

References

  • 1.

    Hui DS, Azhar EI, Madani TA, Ntoumi F, Kock R, Dar O, et al. The continuing 2019-nCoV epidemic threat of novel coronaviruses to global health - The latest 2019 novel coronavirus outbreak in Wuhan, China. Int J Infect Dis. 2020; 91:264-6. [DOI:10.1016/j.ijid.2020.01.009] [PMID] [PMCID].

  • 2.

    World Health Organization. WHO Director-General's opening remarks at the media briefing on COVID-19 [Internet]. 2020 [Updated 2020 March 11]. Available from: https://www.who.int/director-general/speeches/detail/whodirector-general-s-opening-remarks-at-the-media-briefing-oncovid-19---11-march-2020.

  • 3.

    Johns Hopkins University & Medicine. COVID-19 dashboard by the Center for Systems Science and Engineering (CSSE) at Johns Hopkins University [Internet]. 2020 [Updated 2020]. Available from: https://coronavirus.jhu.edu/map.html.

  • 4.

    Centers for Disease Control and Prevention (CDC). Symptoms of COVID-19 [Internet]. 2020 [Updated 2020]. Available from: https://www.cdc.gov/coronavirus/2019-ncov/symptoms-testing/symptoms.html.

  • 5.

    Murthy S, Gomersall CD, Fowler RA. Care for critically Ill patients with COVID-19. JAMA. 2020; 323(15):1499-500. [DOI:10.1001/jama.2020.3633] [PMID].

  • 6.

    World Health Organization. Multisystem inflammatory syndrome in children and adolescents temporally related to COVID-19: Scientific brief [Internet]. 2020 [Updated 2020 May 15]. Available from: https://www.who.int/news-room/commentaries/ detail/multisystem-inflammatory-syndrome-inchildren-and-adolescents-with-covid-19.

  • 7.

    Qin Ch, Zhou L, Hu Z, Zhang Sh, Yang Sh, Tao Y, et al. Dysregulation of immune response in patients with Coronavirus 2019 (COVID-19) in Wuhan, China. Clin Infect Dis. 2020; 71(15):762-8. [DOI:10.1093/cid/ciaa248] [PMID] [PMCID].

  • 8.

    de Wit E, van Doremalen N, Falzarano D, Munster VJ. SARS and MERS: Recent insights into emerging coronaviruses. Nat Rev Microbiol. 2016; 14(8):523-34. [DOI:10.1038/nrmicro. 2016.81] [PMID] [PMCID].

  • 9.

    Coronaviridae Study Group of the International Committee on Taxonomy of Viruses. The species Severe acute respiratory syndrome-related coronavirus: Classifying 2019-nCoV and naming it SARS-CoV-2. Nat Microbiol. 2020; 5(4):536-44. [DOI:10.1038/s41564-020-0695-z] [PMID] [PMCID].

  • 10.

    Fehr AR, Perlman S. Coronaviruses: An overview of their replication and pathogenesis. In: Maier H, Bickerton E, Britton P, editors. Coronaviruses. Methods in Molecular Biology. Vol. 1282. New York, NY: Humana Press. [DOI:10.1007/978-1-4939-2438-7_1] [PMID] [PMCID].

  • 11.

    Centers for Disease Control and Prevention (CDC). How COVID-19 spreads [Internet]. 2020 [Updated 2020]. Available from: https://www.cdc.gov/coronavirus/2019-ncov/preventgetting-sick/how-covid-spreads.html.

  • 12.

    World Health Organization. Q & A on coronaviruses (COVID-19) [Internet]. 2020 [Updated 2020 April 22]. Available from: Not Found Link.

  • 13.

    Chen G, Wu D, Guo W, Cao Y, Huang D, Wang H, et al. Clinical and immunological features of severe and moderate coronavirus disease 2019. J Clin Invest. 2020; 130(5):2620-9.[DOI:10.1172/JCI137244] [PMID] [PMCID].

  • 14.

    Wang D, Hu B, Hu Ch, Zhu F, Liu X, Zhang J, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA. 2020;323(11):1061-9. [DOI:10.1001/jama.2020.1585] [PMID] [PMCID].

  • 15.

    Zu ZY, Jiang MD, Xu PP, Chen W, Ni QQ, Lu GM, et al. Coronavirus disease 2019 (COVID-19): A perspective from China. Radiology. 2020; 296(2):E15-25. [DOI:10.1148/radiol.2020200490][PMID] [PMCID].

  • 16.

    Li LQ, Huang T, Wang YQ, Wang ZP, Liang Y, Huang TB, et al. COVID19 patients clinical characteristics, discharge rate, and fatality rate of metaanalysis. J Med Virol. 2020; 92(6):577-83. [DOI:10.1002/jmv.25757] [PMID] [PMCID].

  • 17.

    Wong CK, Lam CW, Wu AK, Ip WK, Lee NL, Chan IH, et al. Plasma inflammatory cytokines and chemokines in severe acute respiratory syndrome. Clin Exp Immunol. 2004; 136(1):95-103.[DOI:10.1111/j.1365-2249.2004.02415.x] [PMID] [PMCID].

  • 18.

    Zhou P, Yang XL, Wang XG, Hu B, Zhang L, Zhang W, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020; 579(7798):270-3. [DOI:10.1038/s41586-020-2012-7] [PMID] [PMCID].

  • 19.

    Huang Ch, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020; 395(10223):497-506. [DOI:10.1016/S0140-6736(20)30183-5].

  • 20.

    Xu H, Zhong L, Deng J, Peng J, Dan H, Zeng X, et al. High expression of ACE2 receptor of 2019-nCoV on the epithelial cells of oral mucosa. Int J Oral Sci. 2020; 12(1):8. [DOI:10.1038/s41368-020-0074-x] [PMID] [PMCID].

  • 21.

    Verdecchia P, Cavallini C, Spanevello A, Angeli F. The pivotal link between ACE2 deficiency and SARS-CoV-2 infection. Eur J Intern Med. 2020; 76:14-20. [DOI:10.1016/j.ejim.2020.04.037][PMID] [PMCID].

  • 22.

    Pober JS, Sessa WC. Evolving functions of endothelial cells in inflammation. Nat Rev Immunol. 2007; 7(10):803-15. [DOI:10.1038/nri2171] [PMID].

  • 23.

    Hoffmann M, Kleine-Weber H, Schroeder S, Krger N, Herrler T, Erichsen S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020; 181(2):271-80.E8. [DOI:10.1016/j.cell.2020.02.052][PMID] [PMCID].

  • 24.

    Li YC, Bai WZ, Hashikawa T. The neuroinvasive potential of SARSCoV2 may play a role in the respiratory failure of COVID 19 patients. J Med Virol. 2020; 92(6):552-5. [DOI:10.1002/jmv.25728] [PMID] [PMCID].

  • 25.

    Gu J, Han B, Wang J. COVID-19: Gastrointestinal manifestations and potential fecal-oral transmission. Gastroenterology. 2020;158(6):1518-9. [DOI:10.1053/j.gastro.2020.02.054] [PMID][PMCID].

  • 26.

    Levi M, van der Poll T. Inflammation and coagulation. Crit Care Med. 2010; 38(2 Suppl):S26-34. [DOI:10.1097/ CCM.0b013e3181c98d21] [PMID].

  • 27.

    Conti P, Caraffa A, Gallenga CE, Ross R, Kritas SK, Frydas I, et al. IL-1 induces throboxane-A2 (TxA2) in COVID-19 causing inflammation and micro-thrombi: Inhibitory effect of the IL-1 receptor antagonist (IL-1Ra). J Biol Regul Homeost Agents. 2020; 34(5):1623-7. [DOI:10.23812/20-34-4EDIT-65] [PMID].

  • 28.

    Liu Y, Du X, Chen J, Jin Y, Peng L, Wang HH, et al. Neutrophil-tolymphocyte ratio as an independent risk factor for mortality in hospitalized patients with COVID-19. J Infect. 2020; 81(1):e6-12. [DOI:10.1016/j.jinf.2020.04.002] [PMID] [PMCID].

  • 29.

    Amanat F, Stadlbauer D, Strohmeier Sh, Nguyen THO, Chromikova V, McMahon M, et al. A serological assay to detect SARSCoV-2 seroconversion in humans. Nat Med. 2020; 26:1033-6.[DOI:10.1038/s41591-020-0913-5].

  • 30.

    Zheng M, Gao Y, Wang G, Song G, Liu S, Sun D, et al. Functional exhaustion of antiviral lymphocytes in COVID-19 patients. Cell Mol Immunol. 2020; 17(5):533-5. [DOI:10.1038/s41423-020-0402-2] [PMID] [PMCID].

  • 31.

    Feng Z, Diao B, Wang R, Wang G, Wang Ch, Tan Y, et al. The novel severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) directly decimates human spleens and lymph nodes.medRxiv. 2020; March. [DOI:10.1101/2020.03.27.20045427].

  • 32.

    Wan S, Yi Q, Fan Sh, Lv J, Zhang X, Guo L, et al. Characteristics of lymphocyte subsets and cytokines in peripheral blood of 123 hospitalized patients with 2019 Novel Coronavirus Pneumonia (NCP). medRxiv. 2020; February. [DOI:10.1101/2020.02.10.20021832].

  • 33.

    Ni L, Ye F, Cheng ML, Feng Y, Deng YQ, Zhao H, et al. Detection of SARS-CoV-2-specific humoral and cellular immunity in COVID-19 convalescent individuals. Immunity. 2020; 52(6):971-7.E3. [DOI:10.1016/j.immuni.2020.04.023] [PMID] [PMCID].

  • 34.

    Weiskopf D, Schmitz KS, Raadsen MP, Grifoni A, Okba NMA, Endeman H, et al. Phenotype of SARS-CoV-2-specific T-cells in COVID-19 patients with acute respiratory distress syndrome. medRxiv. 2020; May. [DOI:10.1101/2020.04.11.20062349].

  • 35.

    Braun J, Loyal L, Frentsch M, Wendisch D, Georg P, Kurth F, et al. Presence of SARS-CoV-2 reactive T cells in COVID-19 patients and healthy donors. medRxiv. 2020; April. [DOI:10.1101/2020.04.17.20061440].

  • 36.

    Diao B, Wang Ch, Tan Y, Chen X, Liu Y, Ning L, et al. Reduction and functional exhaustion of T cells in patients with coronavirus disease 2019 (COVID-19). Front Immunol. 2020; 11:827.[DOI:10.3389/fimmu.2020.00827] [PMID] [PMCID].

  • 37.

    Zhou Y, Fu B, Zheng X, Wang D, Zhao Ch, Qi Y, et al. Pathogenic T-cells and inflammatory monocytes incite inflammatory storms in severe COVID-19 patients. Natl Sci Rev. 2020; 7(6):998-1002. [DOI:10.1093/nsr/nwaa041] [PMCID].

  • 38.

    Li X, Geng M, Peng Y, Meng L, Lu Sh. Molecular immune pathogenesis and diagnosis of COVID-19. J Pharm Anal. 2020; 10(2):102-8. [DOI:10.1016/j.jpha.2020.03.001] [PMID] [PMCID].

  • 39.

    Prompetchara E, Ketloy Ch, Palaga T. Immune responses in COVID-19 and potential vaccines: Lessons learned from SARS and MERS epidemic. Asian Pac J Allergy Immunol. 2020; 38(1):1-9. [DOI:10.12932/AP-200220-0772] [PMID].

  • 40.

    Zheng HY, Zhang M, Yang CX, Zhang N, Wang XC, Yang XP, et al. Elevated exhaustion levels and reduced functional diversity of T cells in peripheral blood may predict severe progression in COVID-19 patients. Cell Mol Immunol. 2020; 17(5):541-3. [DOI:10.1038/s41423-020-0401-3] [PMID] [PMCID].

  • 41.

    Huang AT, Garcia-Carreras B, Hitchings MDT, Yang B, Katzelnick LC, Rattigan SM, et al. A systematic review of antibody mediated immunity to coronaviruses: Antibody kinetics, correlates of protection, and association of antibody responses with severity of disease. medRxiv. 2020; April. [DOI:10.1101/2020.04.14.20065771].

  • 42.

    Totura AL, Baric RS. SARS coronavirus pathogenesis: Host innate immune responses and viral antagonism of interferon. Curr Opin Virol. 2012; 2(3):264-75. [DOI:10.1016/j.coviro.2012.04.004] [PMID] [PMCID].

  • 43.

    Ju B, Zhang Q, Ge X, Wang R, Yu J, Shan S, et al. Potent human neutralizing antibodies elicited by SARS-CoV-2 infection. bioRxiv. 2020; March. [DOI:10.1101/2020.03.21.990770].

  • 44.

    Wu F, Wang A, Liu M, Wang Q, Chen J, Xia Sh, et al. Neutralizing antibody responses to SARS-CoV-2 in a COVID-19 recovered patient cohort and their implications. medRxiv. 2020; April. [DOI:10.1101/2020.03.30.20047365].

  • 45.

    Adams E, Ainsworth M, Anand R, Andersson MI, Auckland K, Kenneth Baillie J, et al. Evaluation of antibody testing for SARSCov-2 using ELISA and lateral flow immunoassays. medRxiv.2020; April. [DOI:10.1101/2020.04.15.20066407].

  • 46.

    Okba NMA, Mller MA, Li W, Wang Ch, GeurtsvanKessel CH, Corman VM, et al. SARS-CoV-2 specific antibody responses in COVID-19 patients. medRxiv. 2020; March. [DOI:10.1101/2020.03.18.20038059].

  • 47.

    Taylor A, Foo SS, Bruzzone R, Vu Dinh L, King NJC, Mahalingam S. Fc receptors in antibodydependent enhancement of viral infections. Immunol Rev. 2015; 268(1):340-64. [DOI:10.1111/imr.12367] [PMID] [PMCID].

  • 48.

    Quinlan BD, Mou H, Zhang L, Guo Y, He W, Ojha A, et al. The SARS-CoV-2 receptor-binding domain elicits a potent neutralizing response without antibody-dependent enhancement. bioRxiv. 2020; April. [DOI:10.1101/2020.04.10.036418].

  • 49.

    Yang X, Yu Y, Xu J, Shu H, Xia J, Liu H, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: A single-centered, retrospective, observational study. Lancet Respir Med. 2020; 8(5):475-81. [DOI:10.1016/S2213-2600(20)30079-5].

  • 50.

    Parsons PE, Eisner MD, Taylor Thompson B, Matthay MA, Ancukiewicz M, Bernard GR, et al. Lower tidal volume ventilation and plasma cytokine markers of inflammation in patients with acute lung injury. Crit Care Med. 2005; 33(1):1-6. [DOI:10.1097/01.CCM.0000149854.61192.DC] [PMID].

  • 51.

    Centers for Disease Control and Prevention (CDC). Coronavirus disease 2019 (COVID-19) [Internet]. 2020 [Updated 2020]. Available from: https://www.cdc.gov/dotw/covid-19/index.html.

  • 52.

    Jawerth N. How is the COVID-19 virus detected using Real Time RT-PCR? [Internet]. 2020 [Updated 2020]. Available from: https://www.iaea.org/newscenter/news/how-is-the-covid-19-virus-detected-using-real-time-rt-pcr.

  • 53.

    Centers for Disease Control and Prevention (CDC). Real-Time RT-PCR panel for detection 2019-nCoV [Internet]. 2020 [Updated 2020 April 25]. Available from: Not Found Link.

  • 54.

    Martina A, Drosten Ch. Coronavirus-update: Folge 22 [Internet]. 2020 [Updated 2020 March 26]. Available from: https:// www.ndr.de/nachrichten/info/coronaskript146.pdf [In German].

  • 55.

    Broughton JP, Deng X, Yu G, Fasching CL, Servellita V, Singh J, et al. CRISPR-Cas12-based detection of SARS-CoV-2. Nat Biotechnol. 2020; 38(7):870-4. [DOI:10.1038/s41587-020-0513-4] [PMID].

  • 56.

    Smithgall MC, Scherberkova I, Whittier S, Green DA. Comparison of Cepheid Xpert Xpress and Abbott ID now to Roche cobas for the rapid detection of SARS-CoV-2. J Clin Virol. 2020; 128:104428. [DOI:10.1016/j.jcv.2020.104428] [PMID] [PMCID].

  • 57.

    World Health Organization. SARS-CoV-2 Antigen detecting rapid diagnostic test implementation projects [Internet]. 2020 [Updated 2020 November 17]. Available from: https://www.who.int/news-room/articles-detail/sars-cov-2-antigen-detecting-rapid-diagnostic-test-implementation-projects.

  • 58.

    Salehi S, Abedi A, Balakrishnan S, Gholamrezanezhad A. Coronavirus disease 2019 (COVID-19): A systematic review of imaging findings in 919 patients. AJR Am J Roentgenol. 2020; 215(1):87-93. [DOI:10.2214/AJR.20.23034] [PMID].

  • 59.

    Loeffelholz MJ, Tang YW. Laboratory diagnosis of emerging human coronavirus infections - the state of the art. Emerg Microbes Infect. 2020; 9(1):747-56. [DOI:10.1080/22221751.2020.1745095] [PMID] [PMCID].

  • 60.

    Johns Hopkins Center for Health Security. Serology-basedtests for COVID-19 [Internet]. 2020 [Updated 2020 April 18].

  • 61.

    Lequin RM. Enzyme Immunoassay (EIA)/Enzyme-Linked Immunosorbent Assay (ELISA). Clin Chem. 2005; 51(12):2415-8. [DOI:10.1373/clinchem.2005.051532] [PMID].

  • 62.

    Johns Hopkins Center for Health Security. Serology tests for COVID-19. COVID-19 testing toolkit [Internet]. 2021 [Updated 2021 April 26].

  • 63.

    Carter LJ, Garner LV, Smoot JW, Li Y, Zhou Q, Saveson CJ, et al. Assay techniques and test development for COVID-19 diagnosis. ACS Cent Sci. 2020; 6(5):591-605. [DOI:10.1021/ acscentsci.0c00501] [PMID] [PMCID].

  • 64.

    Healagen. COVID-19 IgG/IgM rapid test cassette [Internet]. 2020 [Updated 2020]. Available from: https://www.fda.gov/media/138438/download.

  • 65.

    Postnikova EN, Pettitt J, Van Ryn CJ, Holbrook MR, Bollinger L, Y Sh, et al. Scalable, semi-automated fluorescence reduction neutralization assay for qualitative assessment of Ebola virusneutralizing antibodies in human clinical samples. PloS One. 2019; 14(8):e0221407. [DOI:10.1371/journal.pone.0221407] [PMID] [PMCID].

  • 66.

    Richter MM. Electrochemiluminescence (ECL). Chem Rev. 2004; 104(6):3003-36. [DOI:10.1021/cr020373d] [PMID].

  • 67.

    Huang Y, Yang R, Xu Y, Gong P. Clinical characteristics of 36 non-survivors with COVID-19 in Wuhan, China. medRxiv. 2020; March. [DOI:10.1101/2020.02.27.20029009].

  • 68.

    Yan L, Zhang HT, Xiao Y, Wang M, Sun C, Liang J, et al. Prediction of criticality in patients with severe Covid-19 infection using three clinical features: A machine learning-based prognostic model with clinical data in Wuhan. medRxiv. 2020; March. [DOI:10.1101/2020.02.27.20028027].

  • 69.

    Xiang J, Wen J, Yuan X, Xiong Sh, Zhou X, Liu Ch, et al. Potential biochemical markers to identify severe cases among COVID-19 patients. medRxiv. 2020; March. [DOI:10.1101/2020.03.19.20034447].

  • 70.

    Yang Y, Shen Ch, Li J, Yuan J, Wei J, Huang F, et al. Plasma IP-10 and MCP-3 levels are highly associated with disease severity and predict the progression of COVID-19. J Allergy Clin Immunol. 2020; 146(1):119-27.E4. [DOI:10.1016/j.jaci.2020.04.027][PMID] [PMCID].

  • 71.

    Chen X, Zhao B, Qu Y, Chen Y, Xiong J, Feng Y, et al. Detectable serum severe acute respiratory syndrome coronavirus 2 viral load (RNAemia) is closely correlated with drastically elevated interleukin 6 level in critically Ill patients with coronavirus disease 2019. Clin Infect Dis. 2020; 71(8):1937-42. https://academic.oup.com/cid/article/71/8/1937/5821311.

  • 72.

    Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Zh, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: A retrospective cohort study. Lancet. 2020; 395(10229):1054-62. [DOI:10.1016/S0140-6736(20)30566-3].

  • 73.

    Liu K, Chen Y, Lin R, Han K. Clinical features of COVID-19 in elderly patients: A comparison with young and middle-aged patients. J Infect. 2020; 80(6):e14-e8. [DOI:10.1016/j.jinf.2020.03.005][PMID] [PMCID].

  • 74.

    Tan L, Kang X, Ji X, Li G, Wang Q, Li Y, et al. Validation of predictors of disease severity and outcomes in COVID-19 patients: A descriptive and retrospective study. Med. 2020; 1(1):128-38.E3. [DOI:10.1016/j.medj.2020.05.002] [PMID] [PMCID].

  • 75.

    Brody B. Prednisone and coronavirus: Do corticosteroids make you immunosuppressed and higher risk for COVID-19? [Internet].2020 [Updated 2020]. Available from: https://creakyjoints.org/living-with-arthritis/coronavirus/treatments/prednisone-steroids-immunosuppressing-coronavirus/.

  • 76.

    Xu X, Han M, Li T, Sun W, Wang D, Fu B, et al. Effective treatment of severe COVID-19 patients with tocilizumab. Proc Natl Acad Sci U S A. 2020; 117(20):10970-5. [DOI:10.1073/pnas.2005615117][PMID] [PMCID].

  • 77.

    Rutherford AI, Subesinghe S, Hyrich KL, Galloway JB. Serious infection across biologic-treated patients with rheumatoid arthritis: Results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis. Ann Rheum Dis. 2018; 77(6):905-10. [DOI:10.1136/annrheumdis-2017-212825] [PMID].

  • 78.

    Menon A, Rajendran NK, Chandrachud A, Setlur G. Modelling and simulation of COVID-19 propagation in a large population with specific reference to India. medRxiv. 2020; May. [DOI:10.1101/2020.04.30.20086306].

  • 79.

    Price KN, Frew JW, Hsiao JL, Shi VY. COVID-19 and immunomodulator/ immunosuppressant use in dermatology. J Am Acad Dermatol. 2020; 82(5):E173-5. [DOI:10.1016/j.jaad.2020.03.046] [PMID] [PMCID].

  • 80.

    King A, Vail A, OLeary C, Hannan C, Brough D, Patel H, et al. Anakinra in COVID-19: Important considerations for clinical trials. Lancet Rheumatol. 2020; 2(7):E379-81. [DOI:10.1016/S2665-9913(20)30160-0].

  • 81.

    Sheng CC, Sahoo D, Dugar S, Prada RA, Wang TKM, Abou Hassan OK, et al. Canakinumab to reduce deterioration of cardiac and respiratory function in SARSCoV2 associated myocardial injury with heightened inflammation (canakinumab in Covid19 cardiac injury: The three C study). Clin Cardiol. 2020; 43(10):1055-63. [DOI:10.1002/clc.23451] [PMID] [PMCID].

  • 82.

    Richardson P, Griffin I, Tucker C, Smith D, Oechsle O, Phelan A, et al. Baricitinib as potential treatment for 2019-nCoV acute respiratory disease. Lancet. 2020; 395(10223):E30-1.[DOI:10.1016/S0140-6736(20)30304-4].

  • 83.

    Sterner RM, Sakemura R, Cox MJ, Yang N, Khadka RH, Forsman CL, et al. GM-CSF inhibition reduces cytokine release syndrome and neuroinflammation but enhances CAR-T cell function in xenografts. Blood. 2019; 133(7):697-709. [DOI:10.1182/blood-2018-10-881722] [PMID] [PMCID].

  • 84.

    Calabrese LH. Molecular differences in anticytokine therapies. Clin Exp Rheumatol. 2003; 21(2):241-8. [PMID].

  • 85.

    Rizk JG, Kalantar-Zadeh K, Mehra MR, Lavie CJ, Rizk Y, Forthal DN. Pharmaco-immunomodulatory therapy in COVID-19. Drugs. 2020; 80(13):1267-92. [DOI:10.1007/s40265-020-01367-z] [PMID] [PMCID].

  • 86.

    Pulido JD, Ahmed O, Rasool R, Chappell G, Durrant C, Chappell D. COVID-19 associated chronic ARDS successfully treated with lenzilumab [Internet]. 2020 [Updated 2020 October 1]. Available from: https://osf.io/xusr9/ [DOI:10.31219/osf.io/xusr9].

  • 87.

    Borcherding N, Jethava Y, Vikas P. Repurposing anti-cancer drugs for COVID-19 treatment. Drug Des Devel Ther. 2020; 14:5045-58. [DOI:10.2147/DDDT.S282252] [PMID] [PMCID].

  • 88.

    Uccelli A, de Rosbo NK. The immunomodulatory function of mesenchymal stem cells: Mode of action and pathways. Ann N Y Acad Sci. 2015; 1351:114-26. [DOI:10.1111/nyas.12815][PMID].

  • 89.

    Chen J, Hu Ch, Chen L, Tang L, Zhu Y, Xu X, et al. Clinical study of mesenchymal stem cell treating acute respiratory distress syndrome induced by epidemic influenza A (H7N9) infection: A hint for COVID-19 treatment. Engineering. 2020; 6(10):1153- 61. [DOI:10.1016/j.eng.2020.02.006] [PMID] [PMCID].

  • 90.

    Liang B, Chen J, Li T, Wu H, Yang W, Li Y, et al. Clinical remission of a critically ill COVID-19 patient treated by human umbilical cord mesenchymal stem cells: A case report. Medicine. 2020; 99(31):e21429. [DOI:10.1097/MD.0000000000021429] [PMID] [PMCID].

  • 91.

    Leng Z, Zhu R, Hou W, Feng Y, Yang Y, Han Q, et al. Transplantation of ACE2- mesenchymal stem cells improves the outcome of patients with COVID-19 pneumonia. Aging Dis. 2020;11(2):216-28. [DOI:10.14336/AD.2020.0228] [PMID] [PMCID].

  • 92.

    Bari E, Ferrarotti I, Saracino L, Perteghella S, Torre ML, Corsico AG. Mesenchymal stromal cell secretome for severe COVID-19 infections: Premises for the therapeutic use. Cells. 2020; 9(4):924. [DOI:10.3390/cells9040924] [PMID] [PMCID].

  • 93.

    Raza SS, Khan MA. Mesenchymal Stem Cells: A new front emerge in COVID19 treatment: Mesenchymal Stem Cells therapy for SARS-CoV2 viral infection. Cytotherapy. 2020; July.[DOI:10.1016/j.jcyt.2020.07.002] [PMCID].

  • 94.

    Jewett A, Kos J, Kaur K, Safaei T, Sutanto Ch, Chen W, et al. Natural killer cells: Diverse functions in tumor immunity and defects in pre-neoplastic and neoplastic stages of tumorigenesis. Mol Ther Oncolytics. 2020; 16:41-52. [DOI:10.1016/j. omto.2019.11.002] [PMID] [PMCID].

  • 95.

    Kaur K, Nanut MP, Ko MW, Safaie T, Kos J, Jewett A. Natural killer cells target and differentiate cancer stem-like cells/ undifferentiated tumors: Strategies to optimize their growth and expansion for effective cancer immunotherapy. Curr Opin Immunol. 2018; 51:170-80. [DOI:10.1016/j.coi.2018.03.022][PMID].

  • 96.

    Shimasaki N, Jain A, Campana D. NK cells for cancer immunotherapy. Nat Rev Drug Discov. 2020; 19(3):200-18.[DOI:10.1038/s41573-019-0052-1] [PMID].

  • 97.

    Fujisaki H, Kakuda H, Shimasaki N, Imai Ch, Ma J, Lockey T, et al. Expansion of highly cytotoxic human natural killer cells for cancer cell therapy. Cancer Res. 2009; 69(9):4010-7.[DOI:10.1158/0008-5472.CAN-08-3712] [PMID] [PMCID].

  • 98.

    Seay K, Church C, Zheng JH, Deneroff K, Ochsenbauer Ch, Kappes JC, et al. In vivo activation of human NK cells by treatment with an interleukin-15 superagonist potently inhibits acute in vivo HIV-1 infection in humanized mice. J Virol. 2015; 89(12):6264-74. [DOI:10.1128/JVI.00563-15] [PMID] [PMCID].

  • 99.

    Thom R, Moraes AS, Bombeiro AL, dos Santos Farias A, Francelin C, da Costa TA, et al. Chloroquine treatment enhances regulatory T cells and reduces the severity of experimental autoimmune encephalomyelitis. PloS One. 2013; 8(6):e65913. [DOI:10.1371/journal.pone.0065913] [PMID] [PMCID].

  • 100.

    Wozniacka A, Lesiak A, Narbutt J, McCauliffe DP, Sysa-Jedrzejowska A. Chloroquine treatment influences proinflammatory cytokine levels in systemic lupus erythematosus patients. Lupus. 2006; 15(5):268-75. [DOI:10.1191/0961203306lu2299oa] [PMID].

  • 101.

    Schrezenmeier E, Drner T. Mechanisms of action of hydroxychloroquine and chloroquine: Implications for rheumatology. Nat Rev Rheumatol. 2020; 16(3):155-66. [DOI:10.1038/s41584-020-0372-x] [PMID].

  • 102.

    Gautret P, Lagier JC, Parola P, Hoang VT, Meddeb L, Mailhe M, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: Results of an open-label non-randomized clinical trial. Int J Antimicrob Agents. 2020; 56(1):105949. [DOI:10.1016/j.ijantimicag.2020.105949] [PMID] [PMCID].

  • 103.

    Chen Zh, Hu J, Zhang Z, Jiang Sh, Han Sh, Yan D, et al. Efficacy of hydroxychloroquine in patients with COVID-19: Results of a randomized clinical trial. medRxiv. 2020; March. [DOI:10.1101/2020.03.22.20040758].

  • 104.

    Borba MGS, Val FFA, Sampaio VS, Alexandre MAA, Melo GC, Brito M, et al. Effect of high vs low doses of chloroquine diphosphate as adjunctive therapy for patients hospitalized with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection: A randomized clinical trial. JAMA Netw Open. 2020; 3(4):e208857. [DOI:10.1001/jamanetworkopen.2020.8857][PMID].

  • 105.

    Shamshirian A, Hessami AH, Heydari K, Alizadeh-Navaei R, Ebrahimzadeh MA, Yip GW, et al. Hydroxychloroquine versus COVID-19: A periodic systematic review and meta-analysis. medRxiv. 2020; May. [DOI:10.1101/2020.04.14.20065276].

  • 106.

    Rdel F, Frey B, Gaipl U, Keilholz L, Fournier C, Manda K, et al. Modulation of inflammatory immune reactions by lowdose ionizing radiation: Molecular mechanisms and clinical application. Curr Med Chem. 2012; 19(12):1741-50. [DOI:10.2174/092986712800099866] [PMID].

  • 107.

    Algara M, Arenas M, Marin J, Vallverdu I, Fernandez-Letn P, Villar J, et al. Low dose anti-inflammatory radiotherapy for the treatment of pneumonia by covid-19: A proposal for a multicentric prospective trial. Clin Transl Radiat Oncol. 2020; 24:29-33. [DOI:10.1016/j.ctro.2020.06.005] [PMID] [PMCID]##.